CNS preclinical services
February 23, 2026

🧠 Did you know that Pharmidex offers specialist CNS preclinical services to accelerate neuroscience drug discovery?


At Pharmidex, we provide expert in vivo and ex vivo neurochemistry and neurobehavioural capabilities to support the progression of CNS drug candidates across key readouts including PK, PD, target engagement and efficacy.


Our CNS platform is designed to help you address the complex challenges of developing therapies for neurodegenerative and psychiatric disorders such as Alzheimer’s, Parkinson’s, schizophrenia and depression.


From microdialysis and brain bioanalysis to blood–brain barrier assessment and sophisticated neurobehavioural models, we deliver actionable data to guide confident decision-making in your neuroscience programmes.

Learn more about how Pharmidex can support your CNS research:


 🔗 www.pharmidex.com/CNS

March 26, 2026
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: 📄 “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" 📄 “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
March 24, 2026
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. 🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
March 16, 2026
Pharmidex is proud to be the Networking Sponsor at the Immuno-Oncology & Biomarker Summit in London. Over the next two days, the event provides an opportunity to discuss the latest advances in immuno-oncology, biomarker discovery, and precision medicine. If you’re attending, come and say hello to Ash Alavijeh to connect and explore opportunities to collaborate.
More Posts